- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Antibody
Comment: Dusigitumab is an investigational monoclonal antibody which neutralises circulating insulin-like growth factor (IGF)-I and IGF-2. These growth factors regulate cell growth, survival, differentiation, and transformation. Antibody-mediated ligand neutralisation prevents these growth hormones from activating signalling via both IGF1R and IR-A (insulin receptor isoform A, Uniprot identifier P06213-2, RefSeq protein NP_001073285).
Peptide sequence alignment suggests that dusigitumab is antibody 7-159-1 in patent US7939637 .
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|International Nonproprietary Names|
|GtoPdb PubChem SID||223366082|
|Search PubMed clinical trials||dusigitumab|
|Search PubMed titles||dusigitumab|
|Search PubMed titles/abstracts||dusigitumab|